limited assurance
 
Stock

Investor Information

  • 2013: Bayer stock clearly outperforms DAX with yield of 45 percent
  • Share price above €100 for the first time
  • Board of Management and Supervisory Board propose dividend increase to €2.10 per share for 2013
Performance of Bayer Stock in 2013

The stock market in 2013

International equity markets performed positively

2013 was a good year for the international equity markets thanks to favorable economic prospects and the expansionary monetary policies of the European Central Bank and the U.S. Federal Reserve. After the DAX had topped 8,000 points in March, a brief downturn in April pushed it back below 7,500 and thus to a lower level than at the start of the year. In October, however, the DAX exceeded 9,000 points for the first time in its 25-year history. It closed 2013 at 9,552 points for a gain of about 25 percent on the year.

The European equities index EURO STOXX 50 (performance index) rose by about 22 percent, ending the year at 5,625 points. Market trends in the United States and Japan were also very positive, with the S&P 500 gaining around 30 percent and the Nikkei 225 nearly 57 percent.

Bayer shares above €100 for the first time

Bayer stock posted another excellent performance in 2013, appreciating by 41.8 percent and thus ­outperforming the benchmark sector indices. The EURO STOXX Health Care Index (performance index) rose by 14 percent in 2013, while the EURO STOXX Chemicals Index (performance index) climbed by 19 percent.

Bayer’s share price developed especially positively in the first and fourth quarters. Including the dividend of €1.90 per share paid at the end of April 2013, the return for the year was 45.2 percent. Bayer shares closed 2013 in triple digits at €101.95, close to the annual and all-time high of €103.05.

Our company’s market capitalization more than doubled over the two-year period from year end 2011 to year end 2013. At the end of 2013 Bayer had the highest weighting in the DAX index, at over 10 percent.

More than 90 percent of the roughly 30 equity analysts who regularly rate our company had a buy or hold recommendation on the stock at the end of last year.

Bayer Stock Data[Table 2.1]
2012 2013
Earnings per share 2.91 3.86
Core earnings per share* 5.30 5.61
Gross cash flow per share 5.51 7.05
Equity per share 22.43 25.16
Dividend per share 1.90 2.10
Year-end price** 71.89 101.95
High for the year** 72.95 103.05
Low for the year** 47.97 69.01
Total dividend payment € million 1,571 1,737
Number of shares entitled to the dividend (Dec. 31) million 826.95 826.95
Market capitalization (Dec. 31) € billion 59.4 84.3
Average daily share turnover on German stock exchanges million 2.7 2.1
Price/EPS** 24.7 26.4
Price/core EPS** 13.6 18.2
Price/cash flow** 13.0 14.5
Dividend yield % 2.6 2.1

2012 figures restated

* For details on the calculation of core earnings per share, see Combined Management Report, Chapter 16.3.

** Xetra closing prices (source: Bloomberg)

Bayer retains good refinancing opportunities on the bond market

Issue volume on the corporate bond market in 2013 continued at the high level of the previous year, with interest coupons at a historic low. There was excellent investor interest in corporate bonds, partly because these continued to offer higher yields than government bonds, for example, and partly because of particularly strong demand for the debt of German issuers with diversified global operations. Subordinated debt benefited especially in 2013 following a further significant drop in risk premiums.

The development of risk premiums is apparent from the trend in credit default swaps (CDS). On the ­derivatives market, the price of these tradable insurance contracts, which are used to hedge against default of a borrower, show how market participants rate a company’s credit standing. As can be seen from Graphic 2.2, CDS volatility was relatively low in 2013. From an overall cost point of view, however, the slight drop in risk premiums during the year was more than offset by higher costs resulting from the rise in interest rates.

In April 2013, Bayer used this favorable environment to issue a three-year bond with a nominal volume of €200 million and a floating-rate coupon on attractive terms. In May, we placed a six-year bond with a nominal volume of JPY 10 billion and a fixed-rate coupon of 0.594 percent. The financing situation in 2013 was also marked by the maturing of a €1 billion bond we had issued in 2006 to partially finance the acquisition of Schering, Berlin, Germany. Redemption took place out of operational liquidity without any direct follow-on financing. Further details of outstanding bonds are given in Note [27] to the consolidated financial statements.

Rates for Five-Year Credit Default Swaps (CDS) 2013

Long-term return on Bayer stock well ahead of the market

A long-term investor who purchased Bayer shares for €10,000 five years ago and reinvested all dividends would have seen the value of the position grow to €28,392 as of December 31, 2013, giving an ­average annual return of 23.2 percent.

Long-Term Returns on Bayer Stock in % p. a. (Dividends Reinvested)[Table 2.2]
Annual returns 1 year
2013
3 years
2011–2013
5 years
2009–2013
% % %
Bayer +45.2 +25.9 +23.2
DAX +25.5 +11.4 +14.7
DJ EURO STOXX 50 +21.5 +7.2 +8.5

Dividend increase to €2.10 per share

The Board of Management and the Supervisory Board will propose to the Annual Stockholders’ Meeting that the dividend be increased by €0.20 to €2.10 per share. Thus we once again intend that our stockholders should participate in last year’s positive business performance. The resulting payout ratio of 37 percent calculated on core earnings per share is within our target corridor of 30 to 40 percent (for details on the calculation of core earnings per share, see Chapter 16.3 of the Combined Management Report).

The dividend yield calculated on the share price of €101.95 at year end 2013 amounts to 2.1 percent and the total dividend payment to €1,737 million.

Dividends Per Share
Total Dividend Payment

A sustainable investment

In 2013 Bayer again qualified for inclusion in major sustainability indices that assess companies on the basis of environmental, social and governance (ESG) criteria. Bayer was listed in the FTSE4Good Global and Europe and the Dow Jones Sustainability World indices last year. Following Bayer’s first-time classification as a pharmaceutical company, we were no longer included in the Dow Jones Sustainability Index Europe. Bayer was featured in the Climate Disclosure Leadership Index for the ninth consecutive year. In 2013 we continued our dialogue with current and potential investors who base their investment decisions on ESG criteria. 

International ownership structure

At the end of 2013, approximately 270,000 stockholders were listed in our share register. Bayer has a 100 percent free float as defined by Deutsche Börse, the operator of the Frankfurt Stock Exchange.

An analysis of our ownership structure carried out in the fourth quarter of 2013 shows the international distribution of our capital stock. The highest proportion of our outstanding shares, almost 30 percent, is held by investors in the U.S. and Canada. Bayer has a stable ownership structure that has altered only marginally in recent years.

Ownership Structure by Country

Accolades for capital market dialogue

In 2013 Bayer received several awards for its communications with the capital markets.

We were awarded first place in the IR Magazine Award in the Best Analyst/Investor Meetings category for our regular “Meet Management” conferences. We have garnered first place three times in the ­Thomson Reuters Extel IR Rankings for the best IR work in the Chemicals category. According to a report published by the German Investor Relations Association (DIRK) and the German business magazine Wirtschaftswoche, Bayer is among the best of the DAX 30 companies in terms of its investor relations ­activities. Here we gained second place. Bayer’s IR website was judged the world’s best in the health care sector in the IR Global Rankings 2013 (MZ-Consult, U.S.A.). At the end of the year we relaunched our IR website for stockholders and analysts in light of the growing importance of mobile devices. The new responsively designed site automatically adapts to different formats for PCs, laptops and mobile devices.

We continued to step up our IR activities in 2013, attending 22 broker conferences, holding 22 roadshows and participating in several field trips. These activities took place in a total of 25 financial ­centers. Last year we held “Meet Management” conferences in New York, Leverkusen, and – for the first time – London. This conference format enables small groups of investors and analysts to meet with members of the management boards of Bayer AG and the subgroups for detailed discussions on ­Bayer’s corporate and business development. As in previous years, private investors had an opportunity to find out about our company and our mission “Bayer: Science For A Better Life” at a number of stockholder forums at which the Investor Relations team was represented.

Online annexes


Enter the relevant code given in the printed version of the Annual Report

Bayer Share Price/Dax Index


Last updated: July 28, 2014  Copyright © Bayer AG
http://www.annualreport2013.bayer.com